Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Fast and easy reactor-based production of copper-64 with high molar activities using recoil chemistry

Martin Pressler ab, Christoph Denk ac, Hannes Mikula a and Veronika Rosecker *ac
aInstitute for Applied Synthetic Chemistry, TU Wien, 1060 Vienna, Austria. E-mail: veronika.rosecker@tuwien.ac.at
bInstitute for Atomic and Subatomic Physics, TU Wien, 1020 Vienna, Austria
cCenter for Labelling and Isotope Production (CLIP), TRIGA Center Atominstitut, TU Wien, 1020 Vienna, Austria

Received 25th August 2025 , Accepted 9th October 2025

First published on 21st October 2025


Abstract

Reactor-based production of medically relevant 64Cu is only possible using recoil chemistry. We report highly soluble tert-butyl copper(II) phthalocyanine as the target material. This enables efficient 64Cu recovery through liquid–liquid extraction after neutron capture. The automatable process allows reuse of the target material and achieves a molar activity of 950 MBq μmol−1.


The interest in copper-based radiopharmaceuticals has increased in the past years due to the variety of copper isotopes suitable for theranostic applications. Among the copper isotopes of interest, 64Cu has a medium half-life of 12.7 h and decays either by emission of a β particle (38.5%) to 64Zn or via electron capture (44%) or emission of a β+ particle (17.5%) to 64Ni. It finds application in both positron emission tomography (PET) and molecular radiotherapy.1,2 Copper-64-based radiopharmaceuticals are regularly studied in clinical trials (e.g., [64Cu]Cu-ATSM for hypoxia in tumor tissue) and have even found their place in routine clinical applications for neuroendocrine tumors (NETs) with the FDA approval of [64Cu]Cu-DOTATATE in 2020.3–6 Moreover, [64Cu]CuCl2 itself has been studied for imaging of different types of cancer.7 Due to their prolonged half-life, 64Cu-labeled antibodies are studied as well.8

Copper-64 can be produced in cyclotrons via proton-induced reactions or in nuclear reactors via neutron capture. Currently, it is produced mostly via the 64Ni(p,n)64Cu nuclear reaction in biomedical cyclotrons using enriched 64Ni electroplated on a gold or rhodium solid target.9–11 This route is applied routinely in several countries10–13 and yields non-carrier-added 64Cu in high quantity and radionuclidic purity.11,14 Nevertheless, the use of highly enriched 64Ni (natural abundance: 0.9%) and limited availability of cyclotrons with adequate solid target systems restrict the production of 64Cu.

Neutron capture offers two possible production routes for 64Cu via the nuclear reactions of 63Cu(n,γ)64Cu or 64Zn(n,p)64Cu using thermal or fast neutrons, respectively, whereas only the latter one offers access to non-carrier-added 64Cu. Non-carrier-added isotopes are characterized by high molar activities, an important factor in radiopharmaceutical sciences.15,16 The production of 64Cu via the 63Cu(n,γ)64Cu route using thermal neutrons has its limitations due to the chemical identity of 63Cu and 64Cu and therefore the low molar activity of 64Cu.

Szilárd–Chalmers reactions are a possible way to increase the molar activity of 64Cu produced from 63Cu. The recoil energy of the emitted prompt gamma photon exceeds that of chemical bonds, causing the activated nucleus to be released in a chemically distinct form from the target material. This allows for chemical separation and enrichment of the product nucleus and, therefore, the achievement of higher molar activities. Key parameters in this process include the enrichment factor and extraction efficiency. The enrichment factor is defined as the ratio between the calculated molar activity before work-up and the molar activity achieved afterward, with values up to 1000 required for practical applications. Extraction efficiency, which represents the proportion of free radioisotope recovered, should exceed 50% to be considered viable.17

During neutron irradiation (typically close to or in the center of a nuclear reactor core), the target material is exposed to high γ-radiation and temperatures. This limits the choice of target materials mostly to inorganic salts or thermally highly stable complexes. Phthalocyanines have long been known as suitable targets due to their high stability and complexation with various metals.18 Copper(II) phthalocyanine (CuPc) complexes are being investigated for the production of enriched 64Cu, but they lack in their cumbersome work-up, as CuPc is only soluble in concentrated sulfuric acid, making work-up based on liquid–liquid extraction impossible.19–21 Ion exchange-based separation methods yield 64Cu with a molar activity of 625 kBq μmol−1.19–22 It was attempted to simplify the work-up using a water-soluble CuPc derivative, octacarboxyphthalocyanato copper(II), and separation of 64Cu by extraction with an oxine solution in chloroform. This, however, resulted in a very low molar activity of 25 kBq μmol−1.23

We identified tert-butyl copper(II) phthalocyanine (tBu-CuPc) as highly soluble in organic solvents, with a solubility of 93 g L−1 in toluene, enabling fast, easily automatable liquid–liquid extraction without the need for hazardous sulfuric acid. tBu-CuPc is readily available from commercial suppliers or can be synthesized from inexpensive starting materials, 4-tert-butylphthalic anhydride and urea.24 Its high solubility allows efficient extraction of free 64Cu from the target material using diluted acids, yielding [64Cu]CuCl2 in a ready-to-use aqueous solution. Following neutron capture in a research reactor, the target was dissolved in toluene, and free 64Cu was extracted with diluted hydrochloric acid (see Fig. 1). To reduce radiation exposure and explore semi-automation, all steps were performed using interconnected vials. After toluene removal and flash chromatography purification, the target material tBu-CuPc can be reused without performance loss.


image file: d5dt02046h-f1.tif
Fig. 1 Schematic representation of the 64Cu production cycle, including the fast and easy synthesis of the target material tBu-CuPc and the setup of the extraction process.

Synthesis of the target material was straightforward from 4-tert-butylphthalic anhydride and urea under catalysis of ammonium heptamolybdate in a microwave reactor at 180 °C for 10 minutes without solvent. Purification was performed using normal phase (NP) chromatography and ethyl acetate/petroleum ether after extraction with diluted hydrochloric acid to remove unreacted inorganic copper. The purchased target material was used without further purification. The typical production process started from the preparation of the target by weighing tBu-CuPc (25–35 mg) in a plastic vial or quartz glass tube. The latter one was sealed using a glass-blowing torch after careful removal of any remaining target material on the top edges. Irradiation experiments were carried out in a TRIGA Mark II research reactor at the lateral (plastic vial) or central (quartz glass tube) irradiation position for up to 8 h at 250 kW. The lateral irradiation position comprises a dry irradiation tube suitable for non-sealed plastic vials, whereas the central irradiation position requires samples sealed in quartz glass as the sample is placed directly in the reactor tank at a wet irradiation position. The irradiated samples were allowed to rest for at least one hour to minimize background radiation from the short-lived co-produced 66Cu (t1/2 = 5.1 min).

After decay of 66Cu, the target material was dissolved in toluene (25–40 mL) and transferred into a separation funnel equipped with two tubes, one for ventilation and one leading to a separate vial. The extraction medium (4–7 mL of 0.8% hydrochloric acid) was added and thoroughly mixed for 30 seconds. After separation of the layers, the aqueous layer containing extracted 64Cu was transferred to the connected empty vial under reduced pressure using a syringe connected to the vial. The extraction was repeated twice and samples from the organic and aqueous phases were taken after each extraction step. The total time from the end of irradiation until the first extraction took 1.5 hours.

The organic samples were analyzed using radio-thin layer chromatography (radio-TLC) for the determination of free 64Cu in the organic phase (see Fig. 2) before extraction. Aqueous samples were used to determine the activity and total copper content using a dose calibrator and inductively coupled plasma optical emission spectroscopy (ICP-OES) measurements, respectively. We investigated our approach towards parameters depending on the target material (purchased vs. synthesized), irradiation position (central vs. lateral) and recycling of the target material. Furthermore, we optimized the extraction process and analyzed the in-house synthesized target material towards the possible formation of the unwanted side product tert-butyl molybdenum(IV) oxophthalocyanine (tBu-MoOPc).


image file: d5dt02046h-f2.tif
Fig. 2 (A) Target material tBu-CuPc sealed in a quartz glass tube before irradiation at the central irradiation position. (B) TLC (left) and radio-TLC (right) of the organic phase performed directly after irradiation of the target material showing 97% of free 64Cu in the origin and 3% of 64Cu activity remaining in the target material.

Due to the use of ammonium heptamolybdate as a catalyst in the synthesis of tBu-CuPc, the formation of tBu-MoOPc as a side product is possible. Neutron activation analysis of the in-house synthesized material showed no formation of tBu-MoOPc during microwave synthesis, as no 99Mo (Eγ = 140 keV) was detectable. Radio-TLC of the irradiated target material dissolved in toluene showed 97% of free copper-64 (Rf = 0) and only 3% of 64Cu bound to the target material (Rf = 1). This indicates a very low retention of 64Cu, which is favorable for high activity production of 64Cu.

A comparison between the purchased and in-house synthesized tBu-CuPc revealed differences when the purchased material was used without purification prior to irradiation. The non-purified commercial tBu-CuPc exhibited lower enrichment factors, extraction efficiency, and molar activity, likely due to its stated purity of only 97%. However, purification of the purchased material through extraction with hydrochloric acid and flash chromatography before irradiation resulted in performances comparable to those of the in-house synthesized material. Furthermore, the target material was reusable across several production cycles when purified via flash chromatography between cycles. The purification step in-between cycles guarantees no decrease in the enrichment factor, extraction efficiency or molar activity.

A comparison between the irradiation positions showed the central position resulting in higher activities for similar target sizes, due to its fivefold higher neutron flux compared to the lateral irradiation position. However, a higher enrichment factor (>1200), extraction efficiency (>59%) and molar activity (>950 MBq μmol−1) could be achieved at the lateral irradiation position, whereas at the central irradiation position, 276, 42.8% and 785 MBq μmol−1 of enrichment factor, extraction efficiency and molar activity, respectively, were obtained (see Table 1). This difference is most likely due to the increased radiolysis of the target material in the center of the reactor as the γ-radiation dose is higher at the lateral position.25 The influence of the γ-radiation dose on the Szilárd–Chalmers production of 64Cu was investigated intensively recently, and a decrease in the molar activity was observed with a higher γ-radiation dose during neutron capture.22 In the second extraction step, 28% of the total activity could be additionally extracted with lower molar activity, independent of the irradiation position. Furthermore, with higher extraction volumes, an increase in the extraction efficiency was observed.

Table 1 Comparison of the irradiation results at the lateral and central irradiation positions including the achieved enrichment factors, extraction efficiencies and molar activities of the first extracts. The achieved molar activity using the lateral irradiation position was higher, most likely due to the higher γ-radiation background in the centre of the reactor, leading to increased decomposition of the target material
Irradiation position Lateral Central
Neutron flux θ [cm−2 s−1] 2 × 1012 1013
Target size [mg] 24 39
Capsule material Plastic Quartz glass
Irradiation time [hh:mm] 08:00 07:15
Activity @EOI [MBq] 25.1 405.0
V (toluene) [mL] 25 40
V (HCl) [mL] 4 7
Enrichment factor [%] 1202 276
Extraction efficiency [%] 59.6 42.8
Molar activity [MBq μmol−1] 953 785


We successfully developed a fast and efficient 64Cu production method based on the Szilárd–Chalmers effect, using highly soluble tert-butyl copper(II) phthalocyanine. Our process is easily automatable and the target material is reusable without losses. This makes our process highly suitable for routine 64Cu production, especially when there is no suitable cyclotron available. Enrichment factors up to 1200 and molar activities exceeding 950 MBq μmol−1 were achieved, both meeting practical requirements. With conventional cyclotron-based 64Cu production, higher activities with about an order of magnitude higher molar activities can be obtained. Both can be further improved by using enriched [63Cu]CuCl2 for the synthesis of [63Cu]tBu-CuPc and irradiation at high flux reactors, potentially achieving three orders of magnitude more copper-64 using similar target size and irradiation time.

Conflicts of interest

VR and CD hold IP (patent number AT525191) on parts of this work.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information containing synthetic details, work-up and recycling procedure is available. See DOI: https://doi.org/10.1039/d5dt02046h.

Acknowledgements

The authors thank the team from the TRIGA Center Atominstitut, TU Wien for their support with irradiation and radiation safety.

References

  1. S. M. Qaim, B. Scholten and B. Neumaier, J. Radioanal. Nucl. Chem., 2018, 318, 1493–1509 CrossRef CAS.
  2. A. Ahmedova, B. Todorov, N. Burdzhiev and C. Goze, Eur. J. Med. Chem., 2018, 157, 1406–1425 CrossRef CAS PubMed.
  3. K. A. Wood, W. L. Wong and M. I. Saunders, Nucl. Med. Biol., 2008, 35, 393–400 CrossRef CAS.
  4. A. L. Vāvere and J. S. Lewis, Dalton Trans., 2007, 4893 RSC.
  5. A. Pfeifer, U. Knigge, J. Mortensen, P. Oturai, A. K. Berthelsen, A. Loft, T. Binderup, P. Rasmussen, D. Elema, T. L. Klausen, S. Holm, E. Von Benzon, L. Højgaard and A. Kjaer, J. Nucl. Med., 2012, 53, 1207–1215 CrossRef CAS PubMed.
  6. C. B. Johnbeck, U. Knigge, A. Loft, A. K. Berthelsen, J. Mortensen, P. Oturai, S. W. Langer, D. R. Elema and A. Kjaer, J. Nucl. Med., 2017, 58, 451–457 CrossRef CAS PubMed.
  7. F. Peng, Nucl. Med. Mol. Imaging, 2022, 56, 80–85 CrossRef CAS.
  8. G. W. Philpott, S. W. Schwarz, C. J. Anderson, F. Dehdashti, J. M. Connett, K. R. Zinn, C. F. Meares, P. D. Cutler, M. J. Welch and B. A. Siegel, J. Nucl. Med., 1995, 36, 1818–1824 CAS.
  9. F. Szelecsényi, G. Blessing and S. M. Qaim, Appl. Radiat. Isot., 1993, 44, 575–580 CrossRef.
  10. D. W. McCarthy, R. E. Shefer, R. E. Klinkowstein, L. A. Bass, W. H. Margeneau, C. S. Cutler, C. J. Anderson and M. J. Welch, Nucl. Med. Biol., 1997, 24, 35–43 CrossRef CAS PubMed.
  11. A. Obata, S. Kasamatsu, D. W. McCarthy, M. J. Welch, H. Saji, Y. Yonekura and Y. Fujibayashi, Nucl. Med. Biol., 2003, 30, 535–539 CrossRef CAS.
  12. L. P. Szajek, W. Meyer, P. Plascjak and W. C. Eckelman, Radiochim. Acta, 2005, 93, 239–244 CrossRef CAS.
  13. S. K. Zeisler, R. A. Pavan, J. Orzechowski, R. Langlois, S. Rodrigue and J. E. Van Lier, J. Radioanal. Nucl. Chem., 2003, 257, 175–177 CrossRef CAS.
  14. Radiopharmaceutical Chemistry, ed. J. S. Lewis, A. D. Windhorst and B. M. Zeglis, Springer International Publishing, Cham, 2019 Search PubMed.
  15. G. Luurtsema, V. Pichler, S. Bongarzone, Y. Seimbille, P. Elsinga, A. Gee and J. Vercouillie, EJNMMI Radiopharm. Chem., 2021, 6, 34 CrossRef PubMed.
  16. H. H. Coenen, A. D. Gee, M. Adam, G. Antoni, C. S. Cutler, Y. Fujibayashi, J. M. Jeong, R. H. Mach, T. L. Mindt, V. W. Pike and A. D. Windhorst, Ann. Nucl. Med., 2018, 32, 236–238 CrossRef.
  17. J.-V. Kratz and K. H. Lieser, Nuclear and Radiochemistry Fundamentals and Applications, Wiley-VCH, Weinheim, Germany, 3rd edn, 2013, vol. 2 Search PubMed.
  18. W. Herr, Z. Naturforsch., B, 1952, 7, 201–207 CrossRef.
  19. E. L. Hetherington, P. J. Sorby and J. Camakaris, Int. J. Rad. Appl. Instr. A, 1986, 37, 1242–1243 CrossRef CAS PubMed.
  20. H. Ebihara, Radiochim. Acta, 1966, 6, 120–122 CrossRef CAS.
  21. T. Chen, M. Yang and S. Yeh, Huaxue, 1976, 7–10 CAS.
  22. J. L. T. M. Moret, T. A. Hardens, O. Van Batenburg, H. T. Wolterbeek, J. R. Van Ommen and A. G. Denkova, Appl. Radiat. Isot., 2020, 160, 109135 CrossRef CAS PubMed.
  23. T. Sekine, K. Kimura and K. Yoshihara, J. Nucl. Sci. Technol., 1986, 23, 1064–1068 CrossRef CAS.
  24. W. Freyer and L. Q. Minh, Monatsh. Chem., 1986, 117, 475–489 CrossRef CAS.
  25. F. M. Lindner, Experimental Measuring and Modelling of Gamma Radiation inside the TRIGA Mark II Reactor at the TU Wien, TU Wien, Vienna, 2024 Search PubMed.

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.